150 related articles for article (PubMed ID: 19021201)
1. Impact of ASC-H terminology on the detection of HSILs in medically underserved California women.
Howell LP; Gurusinghe S; Tabnak F
Diagn Cytopathol; 2009 Feb; 37(2):103-10. PubMed ID: 19021201
[TBL] [Abstract][Full Text] [Related]
2. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing.
Howell LP; Gurusinghe S; Tabnak F; Sciortino S
Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426
[TBL] [Abstract][Full Text] [Related]
3. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria.
Thrall MJ; Pambuccian SE; Stelow EB; McKeon DM; Miller L; Savik K; Gulbahce HE
Cancer; 2008 Jun; 114(3):171-9. PubMed ID: 18454461
[TBL] [Abstract][Full Text] [Related]
4. Role of Pap Test terminology and age in the detection of carcinoma invasive and carcinoma in situ in medically underserved California women.
Howell LP; Tabnak F; Tudury AJ; Stoodt G
Diagn Cytopathol; 2004 Apr; 30(4):227-34. PubMed ID: 15048955
[TBL] [Abstract][Full Text] [Related]
5. Screening for cervical disease in mature women: strategies for improvement.
Colgan TJ; Clarke A; Hakh N; Seidenfeld A
Cancer; 2002 Aug; 96(4):195-203. PubMed ID: 12209660
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
Zhao C; Austin RM
Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
[TBL] [Abstract][Full Text] [Related]
7. Cytologic-histologic correlation of screening and diagnostic Papanicolaou tests.
Chute DJ; Covell J; Pambuccian SE; Stelow EB
Diagn Cytopathol; 2006 Jul; 34(7):503-6. PubMed ID: 16783779
[TBL] [Abstract][Full Text] [Related]
8. Early detection of precursors of cervical cancer with cervical cytology and visual inspection of cervix with acetic Acid.
Dhaubhadel P; Vaidya A; Choudhary P
JNMA J Nepal Med Assoc; 2008; 47(170):71-6. PubMed ID: 18709035
[TBL] [Abstract][Full Text] [Related]
9. [Comment on diagnosis of atypical squamous cells using new the Bethesda system 2001].
Wang Y; Bian ML; Liu J
Zhonghua Fu Chan Ke Za Zhi; 2004 Jan; 39(1):27-9. PubMed ID: 14989984
[TBL] [Abstract][Full Text] [Related]
10. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
11. Significance of subclassifying high-grade squamous intraepithelial lesions into moderate dysplasia/CIN II versus severe dysplasia/CIN III/CIS in the Bethesda System terminology.
Howell LP; Zhou H; Wu W; Davis R
Diagn Cytopathol; 2004 May; 30(5):362-6. PubMed ID: 15108239
[TBL] [Abstract][Full Text] [Related]
12. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.
Cooper CP; Saraiya M; McLean TA; Hannan J; Liesmann JM; Rose SW; Lawson HW
J Womens Health (Larchmt); 2005 Oct; 14(8):670-8. PubMed ID: 16232098
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of a community outreach intervention to improve follow-up among underserved women at highest risk for cervical cancer.
Engelstad LP; Stewart S; Otero-Sabogal R; Leung MS; Davis PI; Pasick RJ
Prev Med; 2005; 41(3-4):741-8. PubMed ID: 16125761
[TBL] [Abstract][Full Text] [Related]
14. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
15. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic verification of Group III and III D cytological tests with special reference to follow-up].
Schlegel H; Kühndel K
Zentralbl Gynakol; 1983; 105(24):1585-96. PubMed ID: 6666444
[TBL] [Abstract][Full Text] [Related]
17. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up.
Massad LS; Seaberg EC; Wright RL; Darragh T; Lee YC; Colie C; Burk R; Strickler HD; Watts DH
Obstet Gynecol; 2008 Jun; 111(6):1388-93. PubMed ID: 18515523
[TBL] [Abstract][Full Text] [Related]
18. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?
Cooper AL; Dornfeld-Finke JM; Banks HW; Davey DD; Modesitt SC
Obstet Gynecol; 2006 Jan; 107(1):71-6. PubMed ID: 16394042
[TBL] [Abstract][Full Text] [Related]
19. Applicability of the Bethesda System 2001 to a public health setting.
Prandi S; Beccati D; De Aloysio G; Fulgenzi P; Gabrielli M; Ghirardini C; Rivasi F; Saragoni L; de Bianchi PS; Bucchi L
Cancer; 2006 Oct; 108(5):271-6. PubMed ID: 16948127
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cervical cancer screening program at a rural community of South Africa.
Hoque M; Hoque E; Kader SB
East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
